Activity

Bimetallic complexes have become an emerging hot topic in field of luminous applications in recent years. Unlike the traditional modification on a cyclometalated ligand, grafting an additional metal ion provides a novel approach to tune molecular conjugation as well as the spin orbital coupling (SOC). Herein, we demonstrate a new kind of binuclear platinum(II) complex Pt-3 that possesses an asymmetric thiophenpyridine-isoquinoline bridging ligand. Compared to its mononuclear analogues of Pt-1 and Pt-2, an extremely large redshift emission from 576 and 618 nm to 721 nm was observed in solution. Binding of two metal ions helps to enhance molecular planarity, extend conjugation and suppress excited state distortion. However, their quantum yields tend to remarkably decrease with increasing red-shift emission as following the “energy gap law”. The relatively larger HOMO/LUMO separation that induced by the second platinum ion also decreases the oscillator strength at the lowest singlet state, and goes against the fast radiative decay process. Solution-processed organic light-emitting diodes (OLEDs) based on Pt-1, Pt-2 and Pt-3 achieved external quantum efficiencies (EQEs) and luminance/radiant emittance of 13.6% and 13640 cd/m2 , 3.5% and 3754 cd/m2 , 0.9% and 7981 mW/Sr/m2 with the corresponding electroluminescent (EL) emission peaked at 580 nm, 625 nm and 708 nm, respectively. This work emphasizes the complement argument of the commonly largely reported symmetric binuclear configurations, and provides a new view to photophysical mechanism and design strategies for bimetallic species.

The purpose of this article is to review the extant literature on bedside teaching rounds within the context of ward rounds performed with the entire clinical team at the patient’s bedside, and to assess the effects of standardisation of this process on patient and learner satisfaction, as well as other duty-hour restrictions and patient care metrics in the academic inpatient setting. Ultimately, the intent of this review is to inform faculty development sessions for educators on the benefits and challenges of standardised rounding protocols.

We performed a search of PubMed, Scopus and CINAHL databases (from 2003 to August 2019). Randomised, controlled trials, pre- and post-interventional studies and cohort studies, in English, were eligible for inclusion. Two reviewers independently searched, screened and analysed the studies, and a narrative synthesis was performed. Articles were evaluated methodologically using the Medical Education Research Quality Study Instrument (MERQSI).

Five articles were included, with one randomised controlled trial, three cohort studies, and one pre- and post-interventional study. Lirametostat manufacturer The collective MERSQI score for the studies was 12.3. Patient satisfaction increased uniformly across studies when standardised practices were used. Attempts to improve learner satisfaction, however, achieved mixed results. In addition, the time of bedside rounds was found to decrease with standardised interventions overall.

In light of generally positive albeit limited evidence for standardised rounding practices, faculty development initiatives might use these data to inform and educate faculty members regarding the use of standardised protocols for bedside rounds.

In light of generally positive albeit limited evidence for standardised rounding practices, faculty development initiatives might use these data to inform and educate faculty members regarding the use of standardised protocols for bedside rounds.Functionalized nanogaps embedded in nanopores show a strong potential for enhancing the detection of biomolecules, their length, type, and sequence. This detection is strongly dependent on the features of the target biomolecules, as well as the characteristics of the sensing device. In this work, through quantum-mechanical calculations, we elaborate on representative such aspects for the specific case of DNA detection and read-out. These aspects include the influence of single DNA nucleotide rotation within the nanogap and the current-voltage (I-V) characteristics of the nanogap. The results unveil a distinct variation in the electronic current across the functionalized device for the four natural DNA nucleotides with the applied voltage. These also underline the asymmetric response of the rotating nucleotides on this applied voltage and the respective variation in the rectification ratio of the device. The electronic tunneling current across the nanogap can be further enhanced through the proper choice of an applied bias voltage. We were able to correlate the enhancement of this current to the nucleotide rotation dynamics and a shift of the electronic transmission peaks towards the Fermi level. This nucleotide specific shift further reveals the sensitivity of the device in reading-out the identity of the DNA nucleotides for all different configurations in the nanogap. We underline the important information that can be obtained from both the I-V curves and the rectification characteristics of the nanogap device in view of accurately reading-out the DNA information. We show that tuning the applied bias can enhance this detection and discuss the implications in view of novel functionalized nanopore sequencers.

Lung cancer patients with mutations in epidermal growth factor receptor (EGFR) gene are treated with tyrosine kinase inhibitor (TKI).

We aimed to evaluate polymerase chain reaction (PCR)-high-resolution melting (HRM), restriction fragment length polymorphism (RFLP), and direct sequencing (DS) to detect EGFR mutations in cell-free DNA (cfDNA) before and after TKI treatment in real-world settings of a developing country.

Paired cytology and plasma samples were collected from 116 treatment-naïve lung cancer patients. DNA from both plasma and cytology specimens was isolated and analyzed using PCR-HRM (to detect exon 19 insertion/deletion), RFLP (to genotypes L858R and L861Q), and DS (to detect uncommon mutations G719A, G719C, or G719S [G719Xaa] in exon 18 and T790M and insertion mutations in exon 20).

EGFR genotypes were obtained in all 116 (100%) cfDNA and 110/116 (94.82%) of cytological specimens of treatment-naïve patient (baseline samples). EGFR-activating mutations were detected in 46/110 (40.6%) plasma samples, and 69/110 (63.